Efficacy of Dimethyl Fumarate Treatment for M...

Efficacy of Dimethyl Fumarate Treatment for Moderate-To-Severe Plaque Psoriasis: A Review

Author Name : Raju K Dhavale, Omkesh R Gharge, Chaitali B Bornare, Amol B Mahale, Pooja N Aher

ABSTRACT

Psoriasis is a chronic inflammatory skin disease with a strong genetic predisposition and autoimmune pathogenic trials. The mostcommon type of psoriasis isplaque psoriasis. It’s a typically appears as raised areas of inflamed skin covered with silvery-white scaly skin this area is called plaque. The dimethyl fumarate (DMF) is decreasing inflammation and preventing nerve damage that may cause symptoms of multiple sclerosis. The fumaric acid esters (FAE) were first investigated for the treatment of psoriasissince 1959. The main activity of DMF and FAE is considered to be immune modulatory resulting in a shift in T helper cell (Th) from the Th1 and Th17 profile Th2 Phenotype. Efficacy was assessed based on the regional PASI Scores and Body Surface Area. Mean percentage changes from baseline in PASI (severity level of 0 or 1 in signs of psoriasis) and DLQI were compared using one-way analysis of variance.Correlation between change from baseline PASI score and DLQI score at week 16 was analysed using a Pearson correlation coefficient.DMF is thought to be the main active FAE in the treatment of psoriasis, according to the both preclinical and clinical evidence, the adverse event is usually mild, and most commonly include gastrointestinal symptom’s and other common adverse event include flush leukocytopenia and lymphopenia.  

Keywords: Plaque Psoriasis, Dimethyl Fumarate, Fumaric Acid Ester, Efficacy